MGMT and neoplasm: No significant differences were found among BMI subsets for clinical features of sex, age, epilepsy history, usage of the anti-epilepsy drug, usage of enzyme-inducing anti-epilepsy drug (EIAED), heart disease history, hypertension, diabetes, trauma history, family history of malignancy, history of cerebrovascular disease, number of lesion(s), location of lesion(s), tumor volume, excision extension, IDH 1/2 mutation, MGMT promoter methylation, TERT promoter mutations, and integrated diagnosis.